47 related articles for article (PubMed ID: 37908459)
1. FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum.
Singh S; Bradford D; Li X; Mishra-Kalyani PS; Shen YL; Wang L; Zhao H; Xiong Y; Liu J; Charlab R; Kraft J; Khasar S; Miller CP; Rivera DR; Kluetz PG; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2024 Jan; 30(1):23-28. PubMed ID: 37624421
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib administration reduced lymphatic malformations in a mouse model and in patients.
Delestre F; Venot Q; Bayard C; Fraissenon A; Ladraa S; Hoguin C; Chapelle C; Yamaguchi J; Cassaca R; Zerbib L; Magassa S; Morin G; Asnafi V; Villarese P; Kaltenbach S; Fraitag S; Duong JP; Broissand C; Boccara O; Soupre V; Bonnotte B; Chopinet C; Mirault T; Legendre C; Guibaud L; Canaud G
Sci Transl Med; 2021 Oct; 13(614):eabg0809. PubMed ID: 34613809
[TBL] [Abstract][Full Text] [Related]
3. Lymphangioma of the fetal neck within the PIK3CA-related-overgrowth spectrum (PROS): A case report.
Scharf JL; Gembicki M; Dracopoulos C; Hellenbroich Y; Offermann A; Stichtenoth G; Tafazzoli-Lari K; Tharun L; Weichert J
Clin Case Rep; 2021 Jul; 9(7):e04527. PubMed ID: 34306701
[TBL] [Abstract][Full Text] [Related]
4. Letter to the editor: "Body composition measures as a determinant of alpelisib-related toxicity".
Surmeli Z
Breast Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38856884
[No Abstract] [Full Text] [Related]
5. Erratum for the Research Article "Alpelisib administration reduced lymphatic malformations in a mouse model and in patients" by F. Delestre
Sci Transl Med; 2024 May; 16(749):eadq3820. PubMed ID: 38809967
[No Abstract] [Full Text] [Related]
6. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
[TBL] [Abstract][Full Text] [Related]
7. Role of Alpelisib in the Treatment of PIK3CA-Mutated Breast Cancer: Patient Selection and Clinical Perspectives.
Chang DY; Ma WL; Lu YS
Ther Clin Risk Manag; 2021; 17():193-207. PubMed ID: 33707948
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of Hypoglycemia With Alpelisib in Pediatric Patients With
Nasomyont N; Rutter MM; Backeljauw PF
JCEM Case Rep; 2023 Mar; 1(2):luad027. PubMed ID: 37908459
[TBL] [Abstract][Full Text] [Related]
9.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
10. Alpelisib: A Novel Agent for PIK3CA-Related Overgrowth Spectrum.
Nadjkovic K; Lonabaugh K
J Pediatr Pharmacol Ther; 2023; 28(7):590-594. PubMed ID: 38025143
[TBL] [Abstract][Full Text] [Related]
11. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G; Lopez Gutierrez JC; Irvine AD; Vabres P; Hansford JR; Ankrah N; Branle F; Papadimitriou A; Ridolfi A; O'Connell P; Turner S; Adams DM
Genet Med; 2023 Dec; 25(12):100969. PubMed ID: 37634128
[TBL] [Abstract][Full Text] [Related]
12. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib.
Morin G; Degrugillier-Chopinet C; Vincent M; Fraissenon A; Aubert H; Chapelle C; Hoguin C; Dubos F; Catteau B; Petit F; Mezel A; Domanski O; Herbreteau G; Alesandrini M; Boddaert N; Boutry N; Broissand C; Han TK; Branle F; Sarnacki S; Blanc T; Guibaud L; Canaud G
J Exp Med; 2022 Mar; 219(3):. PubMed ID: 35080595
[TBL] [Abstract][Full Text] [Related]
13. Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
Wenger TL; Ganti S; Bull C; Lutsky E; Bennett JT; Zenner K; Jensen DM; Dmyterko V; Mercan E; Shivaram GM; Friedman SD; Bindschadler M; Drusin M; Perkins JN; Kong A; Bly RA; Dahl JP; Bonilla-Velez J; Perkins JA
Genet Med; 2022 Nov; 24(11):2318-2328. PubMed ID: 36066547
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration.
Sullivan KM; Dores GM; Nayernama A; Prowell TM; Pradhan SM; Osgood C; Jones SC
JAMA Oncol; 2022 Oct; 8(10):1503-1505. PubMed ID: 35980660
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
